Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-30, Stock:NVS, The news for the past five days is as follows:
2018-11-23: NEWS1: US benefits manager baulks after Novartis values gene therapy at $4-5 mln.NEWS2: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS3: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS4: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for November 26, 2018.NEWS5: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for November 26, 2018.NEWS6: Novartis Gets Approval for Gene Therapy Luxturna in Europe.NEWS7: Novartis Gets Approval for Gene Therapy Luxturna in Europe.NEWS8: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS9: Novartis's pricing might be tested with costly eye therapy.NEWS10: Novartis Gets Approval for Gene Therapy Luxturna in Europe.NEWS11: U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million.NEWS12: Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval.NEWS13: Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval.NEWS14: Novartis : EU Approves One-time Gene Therapy Luxturna To Restore Vision.NEWS15: Novartis : EU Approves One-time Gene Therapy Luxturna To Restore Vision.
2018-11-26: NEWS1: Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss.NEWS2: Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss.NEWS3: Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss.NEWS4: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS5: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS6: Endocyte Stock Has Seen a Solid Hike in 2018.NEWS7: Health Care Digest: Genentech&apos;s blood cancer win, a boost for Gilead&apos;s HIV PrEP and a tiny IPO swings at antibiotics.NEWS8: Novartis CEO: 4 factors can help the industry price and pay for lifesaving cell and gene therapies.NEWS9: Novartis CEO: 4 factors can help the industry price and pay for lifesaving cell and gene therapies.NEWS10: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS11: European approval of Spark Therapeutics&apos; gene therapy triggers $25M payment.
2018-11-27: NEWS1: Roche buys U.S. biotech Jecure in race for liver disease drugs.NEWS2: Novartis's Alcon sees myopia epidemic driving sales growth.NEWS3: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS4: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS5: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS6: Alcon To Highlight Vision, Strategy, Benefits As Standalone Company Post Spinoff.NEWS7: Alcon To Highlight Vision, Strategy, Benefits As Standalone Company Post Spinoff.
2018-11-28: NEWS1: Celgene & Bluebird's CAR T Therapy Study Completes Enrollment.NEWS2: Celgene & Bluebird's CAR T Therapy Study Completes Enrollment.NEWS3: Novartis (NVS) Receives EC Approval for Neulasta Biosimilar.NEWS4: Celgene & Bluebird's CAR T Therapy Study Completes Enrollment.NEWS5: Novartis' Biosimilar to Amgen's Neulasta Approved in Europe.NEWS6: Glaxo's Horlicks Sale Bid Heats Up, Nestle, Unilever Close In.NEWS7: Glaxo's Horlicks Sale Bid Heats Up, Nestle, Unilever Close In.NEWS8: Novartis joins rush of science companies moving to White City.NEWS9: Glaxo's Horlicks Sale Bid Heats Up, Nestle, Unilever Close In.
2018-11-29: NEWS1: Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma.NEWS2: Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma.NEWS3: Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma.NEWS4: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS5: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS6: Roche (RHHBY) to Acquire Jecure and Enter the NASH Space.NEWS7: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS8: Novartis: EU Approves Gilenya To Treat MS In Children, Adolescents - Quick Facts.NEWS9: Novartis: EU Approves Gilenya To Treat MS In Children, Adolescents - Quick Facts.NEWS10: Novartis (NVS) Receives EC Approval for Neulasta Biosimilar.NEWS11: Novartis (NVS) Receives EC Approval for Neulasta Biosimilar.

Answer: Rise